OPKO Health, Inc.

OPKO Health is a healthcare company operating in two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment focuses on developing innovative therapies, including MDX2001 (a tetra-specific antibody for solid tumors in Phase 1 trials), MDX2003 (for hematological tumors), and MDX2004 (an immune modulator). It also develops an Epstein-Barr virus vaccine and markets Rayaldee (a patented extended-release prohormone for secondary hyperparathyroidism), OPK-88006 (for blood glucose regulation and weight loss), and NGENLA (a recombinant human growth hormone for pediatric growth hormone deficiency). The Diagnostics segment, under the BioReference brand, offers laboratory testing services such as molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare, as well as the 4Kscore test for prostate cancer.

OPKO Health is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol OPK. Its shares are traded in US Dollars (USD). The company is headquartered in Miami, Florida, and operates primarily in the United States, though it has a global presence in the healthcare sector.

OPKO Health operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry encompasses companies that provide diagnostic services, research tools, and related healthcare products. OPKO's dual focus on pharmaceuticals and diagnostics places it at the intersection of drug development and laboratory testing, serving both therapeutic and diagnostic needs.

OPKO Health is headquartered in Miami, Florida, United States. Founded in 2006, the company serves global markets through its Pharmaceutical and Diagnostics segments. Its pharmaceutical products target conditions such as cancer, metabolic disorders, and growth hormone deficiency, while its diagnostics division, BioReference, provides laboratory testing services primarily in the US, including esoteric testing, molecular diagnostics, and correctional healthcare. The company's global reach is supported by its research and development efforts and its portfolio of patented therapies.

OPKO Health generates revenue through two main segments. The Pharmaceutical segment earns from the sale of approved drugs like Rayaldee (for secondary hyperparathyroidism) and NGENLA (for pediatric growth hormone deficiency), as well as from licensing and development milestones for pipeline candidates such as MDX2001 and MDX2003. The Diagnostics segment, operating under the BioReference brand, generates revenue by providing a wide range of laboratory testing services to healthcare providers, including molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. Additionally, the 4Kscore test contributes to diagnostics revenue. The company's business model combines drug development with commercial diagnostic services to create diversified income streams.